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AmyloidOxidative stress is associated with several major ailments. However, it is only recently that the developments in
our molecular level understanding of the consequences of oxidative stress in modifying the chemical structures
of biomolecules, lipids in particular, are beginning to opennewemerging insights into the signiﬁcance of oxidative
stress in providingmechanistic insights into the etiologies of these diseases. In this brief reviewwewill ﬁrst discuss
the role of lipid oxidation in controlling themembrane binding of cytochrome c, a key protein in the control of ap-
optosis.We then present an overviewof the impact of oxidizedphospholipids on the biophysical properties of lipid
bilayers and continue to discuss, how these altered properties can account for the observed enhancement of for-
mation of intermediate state oligomers by cytotoxic amyloid forming peptides associatedwith pathological condi-
tions as well as host defense peptides of innate immunity. In the third part, we will discuss how the targeting of
oxidized phospholipids by i) pathology associated peptides and ii) host defense peptides can readily explain the
observed clinical correlations associating Alzheimer's and Parkinson's diseases with increased risk for type 2 dia-
betes and age-relatedmacular degeneration, and the apparent protective effect of Alzheimer's and Parkinson's dis-
eases from some cancers, as well as the inverse, apparent protection by cancer from Alzheimer's and Parkinson's
diseases. This article is part of a Special Issue entitled: Oxidized phospholipids—Their properties and interactions
with proteins.
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Oxidative stress is associated with apoptosis as well as with a
number of pathological processes, in most cases manifesting as in-
ﬂammation. Major ailments to be mentioned in this context are
atherosclerosis (discussed by Stemmer and Hermetter in this Special
Issue), age-related macular degeneration (AMD), Alzheimer's (AD)
and Parkinson's diseases (PD), prion disease, type 2 diabetes (2DM),
and cancer, as discussed brieﬂy in this review. Reactive oxygen
species (ROS) formed in oxidative stress introduce a plethora of com-
plex chemical modiﬁcations to all biomolecules, proteins, nucleic
acids, and lipids. This review will not deal with small molecules
such malondialdehyde and 4-hydroxy-2-nonenal formed upon ROS
reacting with lipids [1], which because of being highly reactive can
be expected to react locally, at the site of their formation. Instead,
we focus on the properties of somewhat more stable phospholipid
oxidation products such as 1-palmitoyl-2-(9′-oxo-nonanoyl)-sn-
glycero-3-phosphocholine and 1-palmitoyl-2-azelaoyl-sn-glycero-
3-phosphocholine (PoxnoPC and PazePC, respectively, Fig. 1), for
which biophysical data are now emerging and which have also
been shown to exert bioactivity in cellular studies [2]. Because of a
lack of similar biophysical data both hydroxy and hydroperoxy de-
rivatives were excluded. Moreover, lipids such as those mentioned
above can be generated in sufﬁcient quantities to yield high enough
local concentrations to have an impact on membrane biophysical
properties, which results in their redistribution via circulation [2,3],
thus producing systemic effects, in particular in conditions associated
with chronic oxidative stress. Reactivity of aldehydophospholipids
with proteins is discussed in detail by Stemmer and Hermetter in this
Special Issue. In this context it is mandatory to remind the reader that
the chemical characterization of oxPL is a rapidly developing ﬁeld
([4]; see also chapter by Reis and Spickett in this Special Issue [104])
and more quantitative studies still remain to be made.
Changes in lipids, phospholipids in particular are of obvious impor-
tance when attempting to understand the consequences of oxidative
stress to membrane associated interactions and processes. Main
organelles responsible for the generation of ROS are the mitochondria
[5,6], which intriguingly also harbor membranes containing major
phospholipid constituents with polyunsaturated fatty acyl (PUFA)
chains, such as tetra-linoleoyl-cardiolipin (tlCL) [7]. While we may
readily assume these lipids to be essential for mitochondrial functions,
they also pose an immediate threat to the structural integrity of thisA) PoxnoPC
B) PazePC
Fig. 1. Chemical structures of the oxidized phospholipids: (A) 1-palmitoyl-2-(9′-oxo-
nonanoyl)-sn-glycero-3-phosphocholine (PoxnoPC) and (B) 1-palmitoyl-2-azelaoyl-
sn-glycero-3-phosphocholine (PazePC).organelle, being highly vulnerable to attack by ROS generated in the mi-
tochondria, for instance following an insult on itsmembrane structure by
aggregated/misfolded protein oligomers composed of intracellular
Alzheimer Aβ-peptide [8]. Importantly, propagation of lipid peroxidation
is a chain reaction, spreading rapidly to adjacent membranes and vicinal
cells [104], and, as pointed out by Bochkov [9] unlike most biochemical
modiﬁcations of cellular constituents this process cannot be controlled
by proteins. One exception to this appears to be the generation of oxPS,
oxPI, and oxCL by cytochrome c [10], this reactionmost likely being con-
trolled by electrostatics between these acidic lipids and cationic domains
of cyt c. Accordingly, the association of cyt c with the above acidic lipids
can be controlled by lipid domain formation, local charge density, pH,
and presence of competing ligands [11–17]. One of the consequences
of the peroxidation ofmitochondrial cardiolipin (tlCL→oxtlCL) is the re-
lease of cytochrome c from mitochondrial membranes [18]. The latter
has been assigned to oxtCL being unable to maintain the cyt c-CL mem-
brane interaction by the extended lipid anchorage [19], which provides
hydrophobic interaction between a membrane associated protein and
the lipid bilayer, without intercalation of the protein into the bilayer.
This mechanism, initially described for cyt c has been subsequently ver-
iﬁed e.g. Orf-9 [20] and bet3 [21]. Recent modiﬁcation of the extended
anchoragemodel for cardiolipin involves extension of two CL acyl chains
into cyt c, with the central glycerol acting as a hinge between the two
connected diacyl esters [22]. In addition to the release of cyt c from the
mitochondria, in itself one of the hallmarks of apoptosis, oxidized mito-
chondrial membrane lipids have been recently implicated also in themi-
tochondrial permeability transition (MPT) [23,24].
The peroxidase activity of cyt c [10] is likely to involve direct contacts
between the cyt c heme and phospholipid PUFA chain, the latter adapt-
ing the so-called extended conformation and accommodating into a hy-
drophobic cavity inside cyt c [12,14,25,26]. The association of cyt to CL is
of high afﬁnity and can result in switching on the peroxidase activity of
cyt c, this step being critical in the early step of the initiation of apoptosis.
The CL interaction has been suggested to involve a conformational
switch to β-sheet structure, in connection to the expression of peroxi-
dase activity [27]. Control of the peroxidase activity of cyt c could repre-
sent another example of functional amyloid formation, with the CL
containing membrane inducing oligomerization of cyt c, yielding a per-
oxidase expressing intermediate. The latter subsequently converts into
inactive, inert amyloid [28,29], directing this potentially toxic protein to-
wards elimination by ﬁrst inactivating it into amyloid, analogous to the
on–off switching of the cytotoxicity of HDP [30] and the catalytic activity
of phospholipase A2 [31,32]. Several lines of research have concluded
lipid membranes to efﬁciently induce the formation of amyloid-type ﬁ-
bers by a number of cytotoxic proteins associated with major degenera-
tive diseases [28,33] as well as those involved in physiological processes
such as apoptosis and innate immunity [34]. Initially, the augmented am-
yloid formation by membranes was associated with negatively charged
lipids and their role was readily explained in terms of concentrating
cationic peptides to themembrane's surface, orienting the attached pep-
tides and with neutralization of their cationic charges allowing for
peptide–peptide interactions, the latter further leading to efﬁcient hy-
drogen bonding promoted by the low dielectric (hydrophobic) mem-
brane environment [30,35,36]. More recent studies have further shown
also oxidized lipids to promote amyloid formation, with major alter-
ations in the aggregation/misfolding free energy landscape [36–38]. In
this context the major classes of proteins/peptides of interest are classi-
ﬁed as intrinsically disordered, lacking structure in solution yet capable
of adapting their conformation to changes in the environment [39].
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by Reis and Spickett in this Special Issue [104]. This review ﬁrst focus-
es on the impact of oxidized phospholipids on the biophysical proper-
ties of lipid membranes. The second part discusses the interactions of
oxidized phospholipids with proteins, with focus on aggregation/
folding/misfolding and amyloid formation on membrane surfaces, ex-
empliﬁed by cytotoxic peptides associated with pathological condi-
tions as well as functional cytotoxic amyloid forming host defense/
antimicrobial peptides (HDP and AMP). The last section summarizes
clinical correlations of relevant pathological conditions, demonstrat-
ing and hopefully convincing the reader that thorough understanding
of the molecular level events described provides a powerful rationale
for explaining the etiology of the above ailments and their relation-
ships observed in clinical work. Notably, this understanding will not
only open new possibilities for rational prevention and intervention,
but also for the development of new curative approaches.Fig. 3. Polarity gradient for a lipid bilayer. Panel A depicts a snapshot from a computer
simulation of a lipid bilayer, while panel B illustrates the time averaged distribution of
the various chemical groups. Panel C shows the position of an amphipathic α-helix re-
siding in the interface, together with the gradient of the membrane polarity.
From [41] by courtesy of Stephen White.2. Brief essentials of biomembranes
The purpose of this section is to introduce to the reader the essential
characteristics of biomembranes and lipid bilayers, aiding in developing
a conceptual molecular level understanding of the key features of pro-
cesses such as lipid-induced amyloid formation. For a more thorough
description the reader is referred to a recent review [36]. The funda-
mental structural motif of all biomembranes is the lipid bilayer with
the bilayer spanning integralmembrane proteins and surface boundpe-
ripheral proteins (Fig. 2), formed by self-assembly and maintained by
and large by the hydrophobic effect [40]. Notably, a key feature missing
in illustrations like the above is the rich scale of structural dynamics of
the membrane and its constituents. In brief, membrane lipids and pro-
teins undergo both lateral and rotational Brownian diffusion in the
plane of the soft undulating membrane. Likewise, the vertical positions
of the lipids with respect to the bilayer are not well deﬁned but ﬂuctu-
ate, with intense conformational dynamics of the hydrocarbon chains.
As a consequence, there is no sharp boundary between the hydrophobic
hydrocarbon phase of the bilayer and the aqueous phase, but the bilayer
structure is best deﬁned as a stochastic ensemble of lipidswith time av-
eraged conformations of their acyl chains and positions of their centers
of mass, with water molecules penetrating to a variable extent towards
the membrane center. A useful and realistic conceptual understanding
can be obtained by describing these bilayer dynamics by themembrane
polarity proﬁle (Fig. 3). Because of the molecular scale of the structure
combined with ﬂuctuations on different length- and timescales the bi-
layer can be regarded as a pseudo-2-D system.Fig. 2. Schematic illustration of the lateral heterogeneity of a biomemIn addition to the above structural dynamics a further level of
complexity is introduced by the vast number of different lipid species
found in living membranes, now estimated to involve tens ofbrane, with the bilayer spanning integral membrane proteins.
Fig. 4. Panel A: the extended conformation adopted by oxidized phospholipid. Panel B: a
critical concentration of OXPL with extended acyl chains causes nucleation corresponding
to a 2-D analog of a micelle and eventually results in phase separation. Extended lipid
phases may also involve interdigitation of the sn-1 chains enhancing the lateral packing
of the lipids within the bilayer.
Table 1
Major pathological conditions and the respective aggregating/misfolding peptides.
Condition Protein/peptides
Alzheimer's disease (AD) Aβ and tau
Age-related macular degeneration (AMD) Aβ and others (drusen)
Parkinson's disease (PD) α-Synuclein
Type 2 diebetes mellitus (2DM) IAPP
Finnish type familial amyloidosis (FAF) Gelsolin
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bilayers harbor a very dynamic and extremely complex pseudo-2-D
chemical environment within the 4-nm thick bilayer slab, offering a
rich variety of chemical structures in an equally rich scale of physico-
chemical environments, yet retaining orientational isotropy, in keeping
with the smectic layer structure of this liquid crystalline mesoscale
assembly.
3. Biophysics of oxidized phospholipids
Realization of the association of oxidative stress and lipid peroxida-
tion with several pathological conditions prompted the ﬁrst phase of
studies on the effects of lipid peroxidation on lipid membrane proper-
ties. Most of these studies were performed with phospholipids isolated
from cells and consisting of lipidmixtures, with a varying degree of acyl
chain unsaturation. As a consequence, upon the induction of lipid per-
oxidation in such mixtures a burst of formation of a complex mixture
of oxidized lipids takes place, involving in addition to the generation
of oxidized lipid species, also the formation of reactive small molecules,
such asmalondialdehyde and 4-hydroxy-2-nonenal. Accordingly, while
results from this type of experiments do to some extent represent the
situation prevailing in real biomembranes exposed to oxidative stress,
deciphering of exact molecular mechanisms becomes ambiguous be-
cause of the poorly-deﬁned complex chemical structures and the lack
of quantitative information. Nevertheless, a number of important re-
sults were obtained. Accordingly, lipid oxidation was shown to cause:
- a loss of the membrane permeability barrier function [43]
- phospholipid phase transitions and phase separation [44]
- cross-linking of phospholipid headgroups, such as ethanolamine
[44]
- augmented phospholipid ﬂip-ﬂop [45]
The latter was explained by an involvement of non-bilayer phase
structures [46]. More recent studies have established altered conforma-
tional dynamics of the oxidatively modiﬁed acyl chains to be responsi-
ble [47].
Of particular interest are PUFA containing phospholipids, which
upon oxidation yield a number of highly reactive derivatives, incorpo-
rating groups such as aldehydes and carboxylic acids at the end of
their acyl chain (Fig. 1). Accommodating these polar moieties within
the low dielectric hydrocarbon phase would be energetically costly
and as a consequence lipids such as those depicted in Fig. 1 will tend
to adopt the extended conformation [25], originally suggested as an in-
termediate lipid conformation in membrane fusion, ﬁrst demonstrated
by ﬂuorescence spectroscopy [48] and subsequently conﬁrmed in com-
puter simulations [49–51]. Adopting the extended conformation causes
the oxidatively modiﬁed chains to reverse their orientation and loop
back into the adjacent aqueous phase. In this context it is of interest
that in phospholipids the majority of acyl chains at the sn-1 carbon
are saturated, whereas unsaturated chains are dominant at the sn-2 po-
sition. The reasons for cells favoring this acyl chain distribution are not
known, yet a functional advantage can be expected. The extended con-
formation is based on the rotation of the C(1)–C(2) bond of the glycerol
backbone [25], which results in the ﬂipping of the direction of the sn-2
chain, maximally by 180°, so as to extend into the aqueous phase. The
unsaturation of the sn-2 chain, particularly for chains such as arachi-
donic, eicosapentaenoic, and docosahexaenoic acidsmakes these chains
less hydrophobic, because of their polarizability [40]. The extended con-
formation was more recently identiﬁed by NMR and was suggested to
being adopted byphospholipids on the surface of cellmembranes, nom-
inated as ‘whiskers’ [52]. This conformation is evident also for phospho-
lipid analogs harboring a ﬂuorescent (polarizable)moiety such as nitro-
2,1,3-benzoxadiaz-ol-4-yl (NBD) at the end of the sn-2 acyl chain [53].
In keeping with the dynamics of the bilayer lipids the oxidatively mod-
iﬁed chains ﬂuctuate between the aligned and extended conformations
[47,54–56]. One of the consequences is that the polarity proﬁle becomesmodiﬁed, allowing water molecules to penetrate deeper and in larger
numbers into the membrane interior [46]. Likewise, the effective polar-
ity of the membrane surface, in the domain accommodating an extend-
ed lipid phase (Fig. 4) decreases (a slab of a more hydrophobic
environment is generated), thus greatly expanding the range of dielec-
tricity associated with the membrane environment.
With sufﬁcient concentration of oxPL with extended acyl chains it is
easy to depict that a critical concentration of extended chains will
cause nucleation of extended lipid domains, such structures correspond-
ing to a 2-D analog of a micelle and eventually resulting in phase separa-
tion (Fig. 4). In such extended lipid phases the average area per lipid
increases and could result in interdigitation of the sn-1 chains, enhancing
the lateral packing of the lipids involved. The decrease in bilayer thick-
nesswill result in the repulsion of lipids such as cholesterol and sphingo-
myelin from these phases, thus driving the formation of liquid ordered
phase enriched domains, as observed in model membranes [57].
An important and physiologically relevant change in the bilayer dy-
namics introduced by oxidatively modiﬁed phospholipids is the in-
creased polarity of the bilayer interior no longer forming a barrier
against accommodating the lipid headgroups in this environment. As
the latter normally attenuates the trans bilayer diffusion (ﬂip-ﬂop) of
membrane lipids, oxidized phospholipids are capable of greatly acceler-
ating this process [47]. This property may be physiologically signiﬁcant
as oxidative stress is associated with processes such as apoptosis and
cancer, both of which also involve a loss in the membrane lipid asym-
metry, resulting e.g. in the exposure of phosphatidylserine on the
outer surface of the plasma membrane. These ﬁndings imply that
there would be no absolute requirement for a membrane enzyme,
‘scramblase’ for the loss of PS asymmetry in these conditions.
4. Membrane associated protein aggregation and misfolding
Protein aggregation andmisfolding into amyloid ﬁbrils are at present
considered to underlie the development of several degenerative dis-
eases, such Alzheimer's and Parkinson's diseases, age-related macular
degeneration (AMD), prion disease, type 2 diabetes, and Finnish type fa-
milial amyloidosis (FAF). In all the above ailments the characteristic ﬁ-
brils are formed by a speciﬁc peptide, viz. Alzheimer Aβ-peptide and
tau (in AD), Aβ (in a mixture of proteins constituting the so-called
Drusen in AMD), α-syn (α-synuclein in PD), prion, and IAPP (islet asso-
ciated polypeptide, amylin in 2DM), and gelsolin fragment (in FAF), re-
spectively, arranging into extended beta-sheet structures (Table 1). The
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for promoting and forming amyloid are now reasonablywell understood
and several algorithms such PASTA, TANGO, and AGGRESCAN [58–60],
have been developed for their identiﬁcation and characterization in pro-
tein sequences. Themechanistic basis was initially assumed to be an un-
derlying mutation, which would make the peptides susceptible for
aggregation and conversion into amyloid. However, between 1 and 5%
of AD is of the early onset form and in these only 5–10% carry amutation,
while in the rest the sequence is normal [61]. Furthermore, also in the
cases with a mutation the disease manifests in themiddle age, thus em-
phasizing a crucial role of the environment, similar to the majority of
cases with normal protein.
Attempts to deﬁne conditions yielding amyloid in a reproducible
manner in vitro have converged in a medium with slightly acidic pH
(about 5.0–5.5) and somewhat lowered dielectricity, obtained by ap-
proximately 30–50% diﬂuoroethanol [62]. Several laboratories could
show that a membrane environment accelerates amyloid formation
[28,37,63–66] in vitro. The signiﬁcance of these ﬁndings is suggested
by the presence of lipids in amyloid deposits isolated from affected
human lesions, asﬁrst demonstrated for Aβ [67]. The bilayermembrane
readily provides a lowdielectric environment [28]. Of particular interest
is the requirement of acidic (negatively charged) phospholipids for pro-
moting ﬁbril formation [35]. The mechanistic basis is likely provided by
the negatively charged membrane accumulating the cationic peptides
onto the surface. In addition, the vectorial nature of the interface can
be readily expected to cause the peptides to align with identical orien-
tation. The negatively charged lipids accumulate protons to the surface,
effectively lowering the effective pH on the membrane [68].
In brief, membranes, particularly when containing acidic, negatively
charged lipids, concentrate cationic peptides/proteins onto their sur-
faces, into a local low pHmilieu. The latter togetherwith the anisotropic
low dielectricity environment of the lipid membrane further forces
polypeptides to align and adjust their conformation so as to enable a
proper arrangement of the amino acid side chains in the hydrophobic
surface, contacting the lipid hydrocarbon region. An important contrib-
uting factor is likely to be neutralization of the positive charges of the
peptide by ion pairing with the negatively charged lipid, emphasizing
the importance of these so-called gate-keeping cationic residues in
amyloidogenic sequences preventing (in the absence of a negatively
charged lipid) by Coulombic repulsion the necessary alignment of the
peptide chains required for β-sheet interaction [30,36]. Concomitantly,
the low dielectricity also forces the polypeptides to maximize intramo-
lecular hydrogen bonding by folding into amphipathic α-helices,
which further aggregate, the latter adding cooperativity to the kinetics
of membrane association [41]. After the above, fast ﬁrst events, sev-
eral slower, cooperative conformational transitions of the oligomeric
polypeptide chains take place in the membrane surface. Relaxation
to the free energy minimum involves a complex free energy land-
scape of the above system composed of a soft membrane interacting
with and accommodating peptide polymers. The overall free energy
landscape thus involves a region of polypeptide aggregation associ-
ated with folding: polypeptide physicochemical properties and avail-
able conformation/oligomerization state spaces as determined by the
amino acid sequence. In this respect, ofmajor interest are those natively
disordered proteins interacting with lipids, which in the absence of a
ligand have no inherent structure and may adapt different functional
states. Key sequence features for lipid and membrane interactions
from the point of view of amyloid formation are i) conformational am-
biguity, ii) adoption of amphipathic structures, iii) ion binding, and iv)
propensity for aggregation and amyloid ﬁbrillation.
The pathways and states of the polypeptide conformational transi-
tions further depend on lipid composition, which thus couples the in-
herent properties of lipid membranes to the inherent properties of
proteins. In other words, different lipids and their mixtures generate a
very complex and rich scale of environments, involving also a number
of cooperative transitions, sensitive to exogenous factors (temperature,ions, pH, and small molecules) with small scale molecular properties
and interactions translating into large scale 2- and 3-D organizational
changes. These lipid surface properties and topologies determine and
couple to the transitions of the added polypeptide, the latter undergo-
ing oligomerization,with a sequence of speciﬁc and cooperative confor-
mational changes.
The above aggregation/folding pathways and transient intermediates
of the polypeptide oligomers appear to have distinct biological functions.
The latter involve i) the control of enzyme catalytic activity [31,32],
ii) cell defense (e.g. antimicrobial and cancer cell killing host defense
peptides/proteins [28,30,69]), and possibly also iii) control of cell shape
and membrane trafﬁc. On the other hand, these processes are also
associated with the onset of major sporadic diseases, associated with
protein misfolding, aggregation and amyloid formation such as in
Alzheimer's and Parkinson's diseases, prion disease, and type 2 diabe-
tes. Exempliﬁed by the latter, in an acidic phospholipid containing
membrane human islet associated polypeptide (IAPP or amylin, secreted
by pancreatic β-cells) efﬁciently transforms into amyloid β-sheet ﬁbrils,
the latter property being associated with established sequence features
of IAPP, involved in aggregation and amyloid formation. IAPP sequence
also harbors anion binding sites, such as those involving cationic side
chain and N-terminal NH-groups of the α-helix. The association with
acidic lipids neutralizes these ‘gatekeeping’ cationic residues, abrogating
electrostatic peptide–peptide repulsion. The subsequent aggregation of
the α-helices involves further oligomerization and a sequence of slow
transitions, driven by hydrogen bonding, ending up as amyloid β-sheet
ﬁbrils. Importantly, the above processing of IAPP in its folding/aggregation
free energy landscape under the inﬂuence of lipid membrane involves
also transient cytotoxic intermediates, which permeabilize membranes,
allowing inﬂux of Ca2+ and triggering of cell death, this process resulting
in the loss of β-cells, causing type 2 diabetes [36]. The ﬁnal, lowest energy
state corresponds to inert and inactive amyloid, the formation of which is
accelerated by acidic phospholipids [70]. It should be stressed that the
actualmolecularmechanisms in these disorders are highly similar reﬂect-
ing the biophysical properties of peptides and their generic sequence re-
quirements for aggregation and formation of amyloid. Likewise, the
involvement of oxidative stress and oxidative modiﬁcation of PUFA con-
taining lipids represent another generic feature of these ailments. Accord-
ingly, it is reasonable to assume that on molecular level a similar chain of
events underlies the loss of tissue function in the disorders discussedhere.
5. Toxic intermediate oligomer
One of the key events in diseases involving protein aggregation and
misfolding is loss of the membrane permeability barrier function, in all
cases due to the emergence of transient cytotoxic protein oligomers
(also called ‘protoﬁbrils’) formed by PAFP, such as Aβ- peptide, α-syn,
prion, and IAPP (islet associated polypeptide, amylin), respectively.
Analogously, transient cytotoxic quaternary structure is involved in
the mechanism of action of HDP [30]. Regarding the latter, this feature
bears major functional advantage to the organism, as follows. The
HDPmonomer is inactive and water soluble and it is just upon its bind-
ing to the target cell surface at sufﬁcient local concentration that results
in peptide aggregation and conformational changes, producing a cyto-
toxic quaternary structure of the oligomer. However, this is just an in-
termediate, transient state, which continues to react and rearrange,
ultimately ending up as mature and inert amyloid, reaching minimum
in the aggregation/misfolding free energy landscape. Accordingly, the
transient toxicity means that upon the completion of the spontaneous,
free energy driven process there remain no toxic oligomers which
would need to be detoxiﬁed by the organism.
The cytotoxicity of the oligomers has been concluded to result from
permeabilization of the membrane lipid bilayer, which accommodated
the peptides and induced, because of proper lipid composition, the olig-
omer formation [28,30,34,69,71,72]. Notably, no protein receptors are
required, and similar toHDP [73] the cytotoxicity of PAfP is independent
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the defects generated in the target membrane by the peptides has been
shown to increase with peptide concentration [75].
6. OxPL promoting amyloid formation
Several groups have demonstrated accelerated amyloid ﬁbril forma-
tion by e.g. Aβ, IAPP, and gelsolin in the presence of membranes con-
taining oxidized lipid species [37,38,65,76]. Our own studies on IAPP
further revealed that while an acidic phospholipid containing bilayer
could rapidly induce IAPP aggregation into mature amyloid ﬁbrils
(Fig. 5, panel A) [70], more complex processes were evident in bilayers
containing the oxidized phospholipid PazePC (Fig. 5, panel B) [76].
These data do reveal that oxPL signiﬁcantly alter the free energy
landscape for the oligomerization of amyloid forming proteins opening
new assembly pathways and prolonging the lifetimes of intermediate
oligomer species existing during the conversion to amyloid beta sheets
[36]. This could underlie the manifestation of cellular toxicity of
amyloidogenic peptides and proteins under pathological conditions
with associated oxidative stress [36] [see also clinical correlations,
below].
The biophysical property of oxPL responsible for promoting
amyloid-type oligomer formation is still unclear, mostly because to a
large extent we are lacking detailed information on the chemistry in-
volved. A very recent study from the laboratory of Hoffmann showed
that oxidation of 1-palmitoyl-2-linoleyl-sn-glycero-3-phosphocholine
and the concomitant reaction of the oxidation products with model
peptides resulted in a complex array of products, with three high
molecular weight phosphatidylcholine derivatives being formed when
reacting with lysine [4]. One possibility is an involvement of Schiff
base intermediates, covalently linking aldehyde-derivatized oxPL
(PoxnoPC) with protein aminogroups [37] and potentially inﬂuencing
the alignment of the reacting peptide in the membrane surface for the
lifetime of the Schiff base and enabling the formation of stable hydrogen
bonded oligomers in a conﬁguration corresponding to a local minimum
in the free energy landscape. More speciﬁcally, the scale of dielectricity
becomes greatly expanded in membranes containing oxPL and forming
extended lipid acyl chain phase (Fig. 4, panel B), thus allowing for a
wider state space of peptide conformations and aggregate structures
for the ensemble of membrane attached peptides, while the presence
of anionic lipids again neutralize the cationic gate-keeping peptide res-
idues, allowing close approach of the peptides. In this connection it is to
be emphasized that the membrane association and intercalation of the
peptides and the progression of the development hydrogen bondingFig. 5. Panel A: amyloid formation by human islet amyloid polypeptide (IAPP, 0.5 μM) in support
and helical tubules formed upon adding IAPP (0.4 μM ﬁnal nominal concentration) to SLB com
labeled aggregated IAPP. The scale bars correspond to 5 μm.
Panel A from [70], and panel B from [76], by courtesy of Kibron Inc.between the peptides together with conformational changes and pep-
tide aggregation all take place simultaneously in the free energy
landscape.
The recent model of amyloid ﬁbril growth by Dill and coworkers
(Fig. 6) draws an analogy between peptide aggregates and hydrophobic-
ity driven formation of amphiphile micelles [77]. Notably, considering
the Schmitt–Ghosh–Dill model in connection to oxPL containing
membranes provides a clear mechanistic rationale for augmented ﬁbril-
lation under these conditions. Accordingly, the hydrophobic residues in
the amyloidogenic peptidesmay act as nucleating surface for lipidmono-
mers, forming a peptide–lipid comicelle aggregate, in keeping with
enhanced amyloid ﬁbril formation in the presence of lipids and surfac-
tants when below their critical micelle concentration, as shown for
apoC-II [78], Aβ-peptide [79], gelsolin fragment [37], and α- and β-syn
[80]. Accordingly, the hydrophobic residues in the amyloidogenic pep-
tides may act as nucleating surface for the lipid monomers, forming a
peptide–lipid comicelle aggregate. Approaching juxtaposed peptide-
oxPL comicells would also further allow for initial antiparallel alignment
and hydrogen bonding of the two peptides, which is likely to have an im-
pact on the possible pathways for further assembly of the oligomers.
7. Clinical correlations and possible future prospects
7.1. Alzheimer's disease
A large body of evidence shows that oxidatively modiﬁed lipids
and their soluble fragmentation products promote amyloid formation
by the Alzheimer Aβ peptide [38,65,81]. Interactions between oxPL
and Aβ play a crucial role in neurotoxic and pathogenic processes in-
volved in AD [82]. Several reports have outlined the potential for a
complex interplay between cholesterol oxidation products and Aβ
[65], and Schiff-based formation by Aβ and aldehyde-bearing lipid
products is known to increase Aβ amyloidogenicity with oxidation
products of cholesterol covalently modifying Aβ and increasing its
amyloidogenicity [83].
7.2. Parkinson's disease
PD is a common neurodegenerative disorder, which affects a large
number of elderly. α-Syn is the major component of Lewy bodies (LB),
cytoplasmic protein aggregates that form in the neurons of PD patients.
α-Syn interacts directly with lipids andmembranes both physiologically
as well as pathologically [84].Work in yeast and othermodel system has
revealed that α-syn-associated toxicity is a consequence of abnormaled lipid bilayers composed of POPC/POPG/BODIPY-PC, 80:20:0.3 (mol/mol). Panel B: Linear
posed of SOPC/PazePC/BODIPY-PC, 80:20:0.5 (mol/mol). Red corresponds to ﬂuorescently
Fig. 6. (Upper) Model for amyloid formation that draws an analogy between peptide aggregates and hydrophobicity driven formation of amphiphile micelles. (Lower) Schematic
representations of the free-energy (F) landscape at low, intermediate, and high peptide concentrations, respectively, at the left, middle, and right.
From [77] by courtesy of Ken Dill).
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estingly, α-syn's association with lipid membranes also accelerates
amyloid ﬁbril formation [86], resulting in LB deposits. Although the mo-
lecular mechanisms associated with neurodegeneration in PD are not
known, it is becoming increasingly evident that lipid peroxidation of do-
paminergic neurons is signiﬁcantly augmented in PD and, consequently
oxPL are formed [87]. Thus, this readily raise the possibility that α-syn
interacting with oxPL precipitates a cascade of events that result in the
formation of cytotoxic α-syn oligomers, and subsequent loss of tissue
function, with the development of PD.
7.3. Type 2 diabetes mellitus
Augmented oxidative stress is associated with type 2 diabetes [88].
Likewise, middle body obesity is a risk factor for DM2 [89], with slow
fractional lipid turnover of the abdominal fat necessarily increasing
lipid peroxidation [90] and subsequent transfer and equilibrium of oxi-
dized lipids through the plasma compartment to all cells. Accordingly,
long termpresence of oxidized lipids in the Langerhansβ-cell outer sur-
face would readily make these cells vulnerable to amyloidogenic attack
by IAPP, present in high concentrations on the surface of the β-cells fol-
lowing secretion of this peptide by these cells.
7.4. Age-related macular degeneration
Age-related macular degeneration (AMD) is a late-onset, neurode-
generative retinal disease that shares several clinical and pathological
featureswith AD [91]. AMD is a heterogeneous disease, which is charac-
terized by morphological and functional abnormalities of the retinal
pigment epithelial (RPE) cells. Degeneration and cell death of RPE
cells cause secondary adverse effects on neural retina leading to vision
loss. AMD is the major cause of blindness in the developed world with
the number of patients increasing due to prolonging average lifespan.
Pathogenesis of AMD strongly associates with oxidative stress,
which involves RPE cell damage caused by ROS. The retinamust endure
a high level of oxidative stress because of its high oxygen consumption,
very high levels of PUFA lipids derived from retinal outer segments and
the extensive exposure to light. It is widely accepted that aging is impli-
cated in increased oxidative damage that leads to protein unfolding,aggregation and as prolonged evoke cell death [92]. Constant exposure
to photo oxidation generated ROS and phagocytosis of the lipid-rich
outer segments expose RPE cells to exceptionally high oxidative stress
that leads to lipofuscin accumulation in lysosomes and a decreased ca-
pacity to degrade cytoplasmic proteins [93]. Daily phagocytosis of con-
sumed photoreceptor outer segments is a critical maintenance function
performed by RPE to preserve vision. Aging RPE accumulates lipofuscin,
which includes N-retinylidene-N-retinylethanolamine (A2E). A2-E has
been shown to be auto-oxidant which inhibits mitochondrial respira-
tion that promotes the unfolding of intracellular proteins [94,95]. In re-
sponse to constant lipid peroxidation lipofuscin, a hallmark of AMD, is
accumulated which decreases lysosomal capacity to degrade lipid-rich
outer segments in postmitotic RPE cells. A delay in outer segment deg-
radation contributes to the development of AMD [91,94,95].
Interestingly, oxidized phospholipids have been observed to be
present in the photoreceptors and RPE cells in themacula region of nor-
mal eyes, and their quantity increases with age. AMD showed more in-
tense immunoreactivity for oxidized phospholipids than age-matched
normal eyes [96]. These ﬁndings suggest that oxidized phospholipids
are involved in the pathogenesis of AMD, similarly to AD. Drugs and nu-
trients that attenuate phospholipid oxidationmay represent a potential
treatment for AMD in future.
In addition to lipofuscin, the presence of extracellular drusendeposits
between the basal lamina of the RPE and the inner collagenous layer of
the Bruch's membrane is common in AMD. Many protein and lipid con-
stituents of drusens are similar to those found in deposits characteristic
of other age-related degenerative disorders, such as AD [91]. These in-
clude Aβ, clusterin, vitronectin, amyloid P, apoE, and inﬂammatory me-
diators, such as acute phase reactants and complement components.
7.5. (Neuro)degenerative disorders and cancer
A large body of literature describes clinical correlations between dif-
ferent degenerative diseases aswell as seemingly distant disorders such
as cancer. The observed increased incidence of 2DM in AD patients [97]
and the observed increased risk of PD in 2DMpatients [98] both suggest
that there is a common underlying mechanism predisposing to these
disorders. Importantly, the processes described above, in particular
the association of chronic oxidative stress in all these diseases, together
Fig. 7. Schematic illustration of the overall process of intrinsically disordered cytotoxic
peptides (IDCP: PAfP orHDP) binding and forming a cytotoxic lipid bilayer permeabilizing
oligomer upon complex formation with oxidatively modiﬁed phospholipids, generated
from PUFA containing phospholipids reacting with reactive oxygen species (ROS).
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mation with prolonged lifetimes of intermediate oligomer species,
would readily provide such unifying mechanism, without any need to
involve more complex scenarios with overlapping cellular signaling
cascades (Fig. 7).
As pointed out recently [99] similar reasoning holds also for the ap-
parent protective effects of PD and AD from some cancers [100,101]. Ac-
cordingly, augmented targeting of HDP to cancer cells with oxPL
containing membranes requires no involvement of cellular signaling
systems [102], but the common feature of systemic oxidative stress in
AD, PD and cancer is sufﬁcient, resulting in increased vulnerability of
neuronal cells to Aβ and α-syn peptides in AD and PD, respectively,
while promoting eradication of cancer cells by HDP [36]. The above
also explains why administration of an antioxidant such as vitamin E
can result in an increased incidence of cancer [103], with the antioxi-
dant diminishing oxidative stress and thus reducing the exposure of
oxPL on the surface of cancer cells, attenuating the efﬁciency of HDP
in eradicating these cells [36].Acknowledgements
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